{"question_id": 1, "annotation_id": "1453073660", "pmcid": "PMC11730665", "question_type": "correct", "table_type": "drug", "expected_answer_p_value": "< 0.001", "expected_answer_significance": "yes", "response": "```json\n{\"p_value\": \"<.001\", \"significance\": \"yes\"}\n```", "response_p_value": "<.001", "response_significance": "yes", "had_paper_context": true, "model": "anthropic/claude-haiku-4-5-20251001"}
{"question_id": 2, "annotation_id": "1453073660", "pmcid": "PMC11730665", "question_type": "modified_variant", "table_type": "drug", "expected_answer_p_value": "not found", "expected_answer_significance": "not found", "response": "```json\n{\"p_value\": \"not found\", \"significance\": \"not found\"}\n```\n\nThe paper reports on rs3765467 in the GLP1R gene (not DPP4), and describes the AG genotype (not TT) as being associated with favorable responses to sitagliptin (P = .023). The specific association described in the question (rs3765467 TT genotype in DPP4 associated with decreased response to sitagliptin) is not found in this study.", "response_p_value": "not found", "response_significance": "not found", "had_paper_context": true, "model": "anthropic/claude-haiku-4-5-20251001"}
{"question_id": 3, "annotation_id": "1453073660", "pmcid": "PMC11730665", "question_type": "modified_drug", "table_type": "drug", "expected_answer_p_value": "not found", "expected_answer_significance": "not found", "response": "```json\n{\"p_value\": \"<0.001\", \"significance\": \"yes\"}\n```", "response_p_value": "<0.001", "response_significance": "yes", "had_paper_context": true, "model": "anthropic/claude-haiku-4-5-20251001"}
{"question_id": 4, "annotation_id": "1453075980", "pmcid": "PMC11730665", "question_type": "correct", "table_type": "drug", "expected_answer_p_value": "< 0.001", "expected_answer_significance": "yes", "response": "```json\n{\"p_value\": \"<0.001\", \"significance\": \"yes\"}\n```", "response_p_value": "<0.001", "response_significance": "yes", "had_paper_context": true, "model": "anthropic/claude-haiku-4-5-20251001"}
{"question_id": 5, "annotation_id": "1453075980", "pmcid": "PMC11730665", "question_type": "modified_variant", "table_type": "drug", "expected_answer_p_value": "not found", "expected_answer_significance": "not found", "response": "```json\n{\"p_value\": \"not found\", \"significance\": \"not found\"}\n```\n\nThe paper reports on rs2909451 TT genotype (not GG) in the DPP-4 gene (not KCNJ11), showing lower efficacy with sitagliptin (p < .001). The specific association described in the question (rs2909451 GG genotype in KCNJ11 with increased response) is not found in this study.", "response_p_value": "not found", "response_significance": "not found", "had_paper_context": true, "model": "anthropic/claude-haiku-4-5-20251001"}
{"question_id": 6, "annotation_id": "1453075980", "pmcid": "PMC11730665", "question_type": "modified_drug", "table_type": "drug", "expected_answer_p_value": "not found", "expected_answer_significance": "not found", "response": "```json\n{\"p_value\": \"not found\", \"significance\": \"not found\"}\n```\n\nThe study reports on rs2285676 in KCNJ11 with sitagliptin (not ifosfamide), but describes the association as involving the **CC genotype** (not GG) being associated with increased response. Specifically, Table 6 shows that patients with rs2285676 CC genotype in the sitagliptin group had a median HbA1c improvement of 1.02 (IQR, 0.90\u20131.22) compared to 1.31 (IQR, 1.08\u20131.42) in the gliclazide group with P < .001. The query asks about GG genotype, which does not match the reported association in the paper.", "response_p_value": "not found", "response_significance": "not found", "had_paper_context": true, "model": "anthropic/claude-haiku-4-5-20251001"}
{"question_id": 7, "annotation_id": "1453075960", "pmcid": "PMC11730665", "question_type": "correct", "table_type": "drug", "expected_answer_p_value": "< 0.001", "expected_answer_significance": "yes", "response": "```json\n{\"p_value\": \"<.001\", \"significance\": \"yes\"}\n```", "response_p_value": "<.001", "response_significance": "yes", "had_paper_context": true, "model": "anthropic/claude-haiku-4-5-20251001"}
{"question_id": 8, "annotation_id": "1453075960", "pmcid": "PMC11730665", "question_type": "modified_variant", "table_type": "drug", "expected_answer_p_value": "not found", "expected_answer_significance": "not found", "response": "```json\n{\"p_value\": \"not found\", \"significance\": \"not found\"}\n```\n\nThe paper reports findings for rs2285676 in the KCNJ11 gene (not KCNQ1), showing that the CC genotype (not GG) was associated with better response to sitagliptin. The specific association described in the question (rs2285676 KCNQ1 GG genotype with decreased response) does not appear in this study.", "response_p_value": "not found", "response_significance": "not found", "had_paper_context": true, "model": "anthropic/claude-haiku-4-5-20251001"}
{"question_id": 9, "annotation_id": "1453075960", "pmcid": "PMC11730665", "question_type": "modified_drug", "table_type": "drug", "expected_answer_p_value": "not found", "expected_answer_significance": "not found", "response": "```json\n{\"p_value\": \"< .001\", \"significance\": \"yes\"}\n```\n\nThe association is found in Table 6 of the paper, which shows that patients with the rs163184 GG genotype in the sitagliptin-treated study group had a median HbA1c improvement of 0.81 (IQR, 0.62\u20130.92) compared with 1.16 (IQR, 0.91\u20131.32) in the gliclazide control group, with a p-value of <.001, indicating statistical significance.", "response_p_value": "< .001", "response_significance": "yes", "had_paper_context": true, "model": "anthropic/claude-haiku-4-5-20251001"}
{"question_id": 10, "annotation_id": "1453076040", "pmcid": "PMC11730665", "question_type": "correct", "table_type": "drug", "expected_answer_p_value": "= 0.053", "expected_answer_significance": "no", "response": "```json\n{\"p_value\": \"0.053\", \"significance\": \"no\"}\n```", "response_p_value": "0.053", "response_significance": "no", "had_paper_context": true, "model": "anthropic/claude-haiku-4-5-20251001"}
